Open access

Rational Categorization of the Pipeline of New Treatments for Advanced Cancer – Prostate Cancer as an Example

Written By

Sarah M. Rudman, Peter G. Harper and Christopher J. Sweeney

Submitted: August 28th, 2012 Published: January 16th, 2013

DOI: 10.5772/53092

Chapter metrics overview

1,962 Chapter Downloads

View Full Metrics

1. Introduction

1.1. The problem

Whilst improvements in patient survival have been realized for a number of haematological and solid malignancies in the last 30 years, new efficacious systemic anti-cancer treatments are still needed. The current, widely used drug development paradigm is often associated with a poor conversion rate from experimental to licensed drug. This process involves a significant investment of resources from sponsors, investigators and patients and to date has only lead to a limited chance of success. At present there are in excess of 800 anti-cancer agents in development and less than 10 new FDA approvals each year [1]. In order to address this problem there has been considerable debate concerning the best trial methodology to rationalize this process, with discussion of the timing, sequence and design of appropriate trials [2]. At present in many tumour types including breast, lung, renal cell and prostate cancer, the pipeline of new agents is crowded. In order therefore to use the available financial and patient resource wisely, it is crucial to identify the key important pathways in oncogenesis that in turn may help and prioritize the drugs with the most promise.

1.2. A promising future

In recent years advances in molecular biology have aided our understanding of the pathogenesis of cancer. This has occurred concurrently with technological advances allowing rational drug design and development (such as tyrosine kinase inhibitors, monoclonal antibodies and anti-sense oligonucleotides). Combining these two advances has been very beneficial in the drug development process such that we now have a wealth of opportunities. The challenge now is how to rationally categorize and prioritize the many strategies that can be deployed. In the discussion below, we propose a rational process to evaluate the merits of different strategies and use prostate cancer as an example. The different strategies include focusing on cytotoxic agents, synthetic lethality strategies, angiogenesis, oncogene addiction pathways and activated survival pathways such as those driven by systems of inflammation and/or metabolism.


2. Building on past successes – Cytotoxics and agents targeting key biological pathways

2.1. Cytotoxic agents

Cytotoxic chemotherapy has had an established role for many cancer types for many decades with the ability to eradicate some cancers, prevent relapse from micrometastatic disease in others and offer life prolonging or palliative benefit in other cancers. With respect to prostate cancer, a role for cytotoxic chemotherapy in the treatment of metastatic castrate refractory prostate cancer (CRPC) was first established using mitoxantrone in 1996, when it was shown to provide effective palliation of pain symptoms compared to prednisolone alone without prolongation of overall survival [3]. This was not associated with a survival benefit and to date the only class of cytotoxic agents to improve survival in metastatic prostate cancer are the taxanes [4]. Docetaxel was licensed in metastatic CRPC patients in 2004 following a phase III study of docetaxel plus prednisone versus mitoxantrone plus prednisone. The taxanes block cells in the G2/M phase of the cell cycle by stabilizing microtubules in the mitotic spindle thereby rendering them unable to separate during mitosis. Cancer cells sensitivity to taxanes is often short lived and resistance develops. The mechanism of this is poorly understood, although over expression of P-glycoprotein and mutations in the tubulin gene have been described [5]. Whilst the non-specific targeting of cycling cells by cytotoxic agents is not classed as targeted therapy, ongoing efforts do exist to introduce new cytotoxic agents to the prostate cancer arena. The aim of improving efficacy and delivery whilst minimizing toxicity underlies this development. In this era of personalized medicine, cytotoxic agents may continue to have a role especially where tumours do not harbour an obvious upregulated or mutated pathway to target. This approach has already led to the development and approval of the synthetic taxane - cabazitaxel for use in the second line metastatic CRPC setting. In the international multicentre phase III TROPIC trial, patients who had progressed on docetaxel were randomized to receive cabazitaxel plus prednisone or mitoxantrone plus prednisone. An improvement in overall survival of 2.4 months was seen (15.1 months versus 12.7 months HR=0.7 p<0.001) [6].

In addition to new members of existing cytotoxic drug classes, new mechanisms of drug delivery continue to be developed. Nanoparticle albumin bound (nab) paclitaxel and docetaxel use albumin as a vehicle to improve drug delivery to the tumour. This approach has proven to be successful using nab-paclitaxel (Abraxane®) in metastatic breast cancer where it delivered a 49% higher dose of drug to patients than a conventional solvent based approach. In addition, higher response rates were seen with an overall response rate of 33% (versus 19% for standard paclitaxel) and increased time to progression from 16.9 to 22 weeks [7]. Both agents are also in development in prostate cancer, where phase II trials are currently evaluating nab-paclitaxel and nab-docetaxel in the CRPC population. Other novel drug delivery strategies include water soluble biodegradable polyglutamate polymer with linked chemotherapeutic molecules (e.g. paclitaxel poligumex, Opaxio®) [8,9] and a nanoparticle bound docetaxel agent (BIND014) has also recently entered phase I clinical trials [10] (Table 1)

Drug Class Study Design Results Current phase of clinical development Reference
Androgen receptor blockers
Abiraterone CYP 17 lyase inhibitor Randomised placebo controlled phase III trial in post-docetaxel and chemo naïve CRPC pts. Overall survival adv 3.9 months in post chemo population
Chemo naïve study stopped early. Median OS not yet reached for Abiraterone
Licensed in post-docetaxel pts
Awaiting license in chemo naïve pts
[26, 28, 29]
Androgen receptor antagonist Phase III randomized placebo controlled AFFIRM study Overall survival adv 4.8 months. Favourable toxicity profile. 0.6% seizure rate Phase III trials in chemo-naïve setting completed accrual [33, 34]
17,20 lyase inhibitor Phase I-II dose escalation study in metastatic CRPC pts accrued. RPIID is 400mg BID, no DLTs Phase II trial accruing in asymp CRPC pts, pts without mets but rising PSA & in combination with docetaxel in met CRPC pts. [30, 31]
TOK-001 AR antagonist, CYP 17 lyase inhibitor, ↓AR levels Phase I-II in CRPC pts (ARMOR1) currently accruing [113]
Histone deacetylase (HDAC) inhibitors
Panobinostat HDAC inhibitor Phase I completed in combination with docetaxel/pred and phase II completed as single agent in CRPC pts Safe as single agent and in combination. IV formulation going forward Phase I-II with Bicalutamide in CRPC pts accruing [37]
Vorinostat HDAC 6 inhibitor Phase I with safety study with docetaxel q21 days and vorinostat q1-14 days
Phase II in post chemo CRPC pts receiving 400mg vorinostat orally
12 pts enrolled but 5 DLTs reported. Trials suspended due to excess toxicity
27 pts but terminated due to excess toxicity.
Significant toxicity seen. 44% G3 AE’s
Phase I in combination with temsirolimus planned [38, 39]
SB939 HDAC inhibitor (multiple classes) Phase I dose escalation trial in solid malignancies MTD 80mg, RPIID 60mg,
DLTs were fatigue, troponin elevation & QTc prolongation
Phase II single agent study in recurrent/met prostate cancer accruing [114]
Romidepsin Depsipeptide
HDAC inhibitor
Phase II in chemo naïve met CRPC pts. 13 mg/m2 q1,8,15 every 28 days 35 pts enrolled. 2 pts had PR "/>6months. 11 pts stopped due to toxicity. N&V, fatigue & anorexia Combination studies with cytotoxic agents planned [115]
HSP90 inhibitors
17-AAG analogue
HSP90 inhibitor
Phase II study in CRPC patients stratified by prior chemotherapy at 400mg/m2 No PSA or RECIST responses seen. G5 ketoacidosis and hepatic failure observed Clinical development ongoing in NSCLC [43]
STA9090 2nd gen
HSP90 inhibitor
Phase I dose escalation studies with IV wkly and twice wkly admin Wkly admin - MTD 216mg/m2 DLTs due to amylase elevation, diarrhoea & fatigue
Twice weekly – MTD as yet not reached
Phase II prostate trials planned [44]
1st gen HSP90 inh Phase II in metastatic CRPC pts. 300mg/m2 weekly for ¾ weeks Trial stopped after 1st phase due to lack of PSA response. G3 fatigue No further prostate trials [41, 42]
siRNA against AR Nanoparticle
In pre-clinical development [10]

Table 1.

The Androgen Receptor pathway

New classes of cytotoxic agents are also in development in prostate cancer. These are members of the epothilone family and the halichondrin B analogue - eribulin. The epothilones are macrolide antibiotics that also act by stabilizing microtubules. They are water soluble and as such do not have to be administered in a lipophilic solution, therefore reducing the allergic reaction rate compared to taxanes. To date the epothilone - ixabepilone is licensed for use in metastatic chemo-refractory breast cancer, although it has also shown activity and acceptable toxicity in a phase II study in a mixed chemo naïve and post chemotherapy CRPC population [11]. Clinical development of several members of this family in prostate cancer continues. Patupilone or naturally occurring Epothilone B and sagopilone (a fully synthetic compound) have also shown activity in post docetaxel and chemo naïve CRPC patients respectively [12, 13].

Eribulin mesylate (or Halaven, Eisai Co.) is a synthetic analogue of the marine sponge natural product Halichondrin B that is a potent naturally occurring mitotic inhibitor. Eribulin binds predominantly with high affinity to the ends of microtubules leading to mitotic arrest and ultimately apoptosis. Eribulin is also licensed for use in metastatic chemotherapy refractory breast cancer patients although a phase II study in both chemotherapy naive and pretreated prostate cancer patients has been performed. Most activity was demonstrated in the chemotherapy naïve cohort with a 22.4% PSA response rate and 8.8% overall response rate [14].

Another successful cytotoxic strategy for targeting prostate cancer metastases with radiation has been the studies using the alpha-emitter Radium 223. This radiopharmaceutical that acts as a calcium mimic can selectively target bone lesions from prostate cancer whilst its low penetrance alpha-emissions are cytotoxic to cancer cells. Its half life of 11.4 days also favours its use as a cancer treatment. Having proven its safety in phase I and II trials [15], the phase III ALSYMPCA trial was stopped early after a pre-planned efficacy interim analysis following recommendations from the independent data monitoring committee on the basis of a significant improvement in overall survival and favourable toxicity profile. In this large study of 922 patients, Radium-223 significantly improved overall survival in patients by 2.8 months (HR 0.695 95% CI 0.552-0.875) in addition to delaying the time to first skeletal-related event by 5.2 months (HR 0.610 95% CI 0.461-0.807) [16].

2.2. Targeting key biological pathways

A leading premise for the treatment for advanced prostate cancer is to target the androgen receptor (AR) axis or to identify cases where a single pathway mutation is thought to drive carcinogenesis. It is proposed that triaging the current pipeline of agents can be directed by building on prior successes. In light of recent advances in our knowledge of AR pathway signaling, further exploration of this pathway is warranted. Moreover, since molecular interrogation of distinct clones driving individual prostate cancers is now possible, treatment of these tumours with agents targeting these mutations would also be desirable. In the past the prostate cancer treatment paradigm has been to expose the patient to an established sequence of agents in a ‘one size fits all’ approach – which may have missed identifying a drug with major activity in a few patients. A strategy that is being increasingly more recognized is the need to characterize a patient’s cancer and select the most appropriate treatment for that cancer phenotype. It is also important to ensure that critical appraisal of pre-clinical and clinical research continues to help guide these endeavors to identify oncogene addiction pathways.


3. Extinguishing the AR axis

The androgen dependence of prostate cancer on testosterone was first observed as early as 1941 when the effect of castration on androgen levels in prostate cancer was studied [17]. This lead to the introduction of androgen deprivation therapy and the generation of the castrate state where serum levels of testosterone are reduced to <50ng/dl or 1.7nmol/l. This treatment is initially effective in 80-90% of patients and results in PSA or radiological responses and clinical improvement in the patient’s symptoms. Eventually, the patient’s cancer progresses despite serum testosterone levels continuing to be low. The current term used to describe this state is ‘castrate resistant prostate cancer’ which has replaced the misleading term ‘hormone-refractory prostate cancer’. CRPC more accurately describes the ongoing dependence of the cancer on AR signaling despite low measureable testosterone levels.

Ligand independent AR signaling is thought to occur in the majority of CRPC tumours via activation of oncogenes such as ERBB2 or H-ras and through MAP kinase signaling [18, 19]. A small proportion of CRPC tumours will also harbour amplifications or point mutations in the ligand-binding domain of the androgen receptor gene leading to altered responsiveness to ligands [20]. A third mechanism of action bypasses androgen receptor in favour of an alternative signaling pathway [21].

The evidence for ongoing androgen sensitivity is also strengthened by the observation of up regulation of AR protein levels in hormone resistant versus hormone sensitive paired xenografts [21] as well as in patient tumour samples [22, 23]. Maintained intra-tumoural levels of testosterone and dihydrotestosterone are also observed despite castrate serum androgen levels [24].

In addition to testicular androgen production, extragonadal sites of androgen synthesis also contribute to testosterone levels. These de novo adrenal and intra-tumoural pathways utilize the 17α-hydroxylase and C17, 20-lyase activity of the CYP17A1 enzyme involved in the steroid biosynthesis pathway. The importance of this pathway was initially clinically exploited with the use of ketoconazole, a weak reversible inhibitor of CYP17. Anti-tumour activity was demonstrated with a PSA response rate of 20-62% in phase II trials and a median duration of response of 3-7 months [25]. However its use was associated with significant toxicity and up to 20% of patients discontinued treatment. This toxicity profile has not been observed with the more potent CYP17 inhibitor abiraterone acetate. This agent has successfully reawakened interest in further manipulation of the AR axis in CRPC patients. After successful phase I and II clinical trial development [26, 27] randomized double blind placebo controlled phase III trials of abiraterone plus prednisolone versus placebo plus prednisolone in chemotherapy naïve and post docetaxel patients were conducted. Results in post docetaxel patients revealed a statistically significant increase in median overall survival of 3.9 months in favour of abiraterone as well as improvements in time to PSA progression, radiological PFS and PSA response rate [28]. More recent results from the interim analysis of chemotherapy naïve patients have also shown significant activity in favour of abiraterone with the interim data monitoring committee recommending unblinding and crossover for patients receiving prednisone alone [29]. Abiraterone was also well tolerated with the predominant toxicities being hypertension, hypokalaemia and fluid retention. These are the expected consequences of the mineralocorticoid excess resulting from the accumulation of precursors upstream of CYP17. These have subsequently been managed with the concomitant use of steroids or the mineralocorticoid antagonist eplerenone.

Orteronel (or TAK 700, Takeda Pharmaceuticals) is another 17,20 lyase inhibitor which has also advanced to phase III CRPC trials after successful phase I and II development [30, 31]. This inhibitor is now in phase III trials as a single agent in asymptomatic CRPC patients and in patients with a rising PSA but no detectable metastatic disease as well as in phase I/II trials in a number of prostate cancer settings including in combination with docetaxel in metastatic CRPC patients.

In addition to steroid biosynthesis inhibitors, further manipulation of the AR axis in castrate patients has been demonstrated using MDV3100 or enzalutamide. First generation anti-androgens such as bicalutamide, flutamide and nilutamide competitively inhibit the AR ligand binding domain. This response is often transient as castration resistance develops which may in part be a consequence of the partial agonist activity of this class [21]. These observations led to the rational design of enzalutamide, an orally available anti-androgen with superior AR binding compared to bicalutamide, and no AR agonist activity in bicalutamide-resistant and AR-over expressing cell lines [32]. A phase I/II study of enzalutamide in 140 post-chemotherapy metastatic CRPC patients demonstrated a PSA response rate of 56% (78/140 patients), soft tissue responses in 22% (13/59 patients), and a median time to progression of 47 weeks. enzalutamide was well tolerated with the most common grade 3 or 4 adverse events being fatigue that resolved with a dose reduction [33]. This activity was confirmed in the multicentre double blind placebo controlled phase III AFFIRM trial comparing enzalutamide against placebo. This trial of 1199 docetaxel pre-treated patients was also stopped early due to a 4.8 months overall survival benefit for enzalutamide compared to placebo with all subgroups benefiting [34].

Other agents in development that manipulate the androgen receptor axis are shown in table 1. In addition to agents intrinsic to the androgen receptor pathway, inhibitors of chaperone proteins may also be important targets. Histone deacetylases (HDAC) are enzymes which remove acetyl groups from proteins and in so doing modulate the protein-protein interactions of co-activators associated with AR binding. HDAC enzymes are over expressed in certain solid tumours including prostate cancer, where high expression levels are associated with poor outcome [35]. HDAC over expression in prostate cancers is also often co-existent with genetic rearrangements in the ETS (E-twenty six) gene family. These genetic alterations have been found in up to 70% of prostate cancers and may interact with HDAC’s already known to be upstream regulators and downstream transducers of the ETS transcription factors family [36]. The preclinical rationale for HDAC inhibition in prostate cancer has led to early phase clinical development of several HDAC inhibitors. Phase I/II studies of panobinostat both as a single agent and in combination with docetaxel confirmed the safety of this approach [37]. In the single arm study, all patients developed progressive disease despite evidence of acetylated histones in peripheral blood mononuclear cells, however 5 out of 8 (63%) patients in the combination study had a ≥ 50% reduction in PSA value. At present a study in combination with bicalutamide in CRPC patients is recruiting. However trials involving single agent vorinostat (an HDAC6 inhibitor known to acetylate tubulin and stabilize microtubules) have been terminated early due to excess toxicity with no significant activity [38, 39].

The other major group of agents that are involved in post-translational modification of the AR axis are heat shock proteins. These are proteins that ensure the maintenance of oncogenic protein homeostasis in the presence of stress factors such as hypoxia or acidotic conditions. Heat shock protein 90 (HSP 90) is an ATP-dependent multi-chaperone complex implicated in the function of the AR. The AR is stabilized by the interaction with HSP 90 that allows it to interact with androgens [40]. Pre-clinical models have shown HSP 90 inhibition leads to decreased AR expression and function and a phase I trial of 17-AAG both as a single agent and in combination with cytotoxic chemotherapy demonstrated drug safety [41]. The subsequent phase II study however failed to reach its primary endpoint and was terminated [42]. Significant toxicity was observed with the 17-AAG analogue retaspmycin (or IPI-504) [43] although clinical development of the second generation HSP90 inhibitor STA9090 has confirmed safety in phase I trials and is proceeding [44]. Studies are planned to determine whether the newer HSP90 agents can hit target and decrease activity with a suitable toxicity profile or whether the therapeutic window is too narrow for safe use of these agents.

In addition, small interfering RNA’s (siRNA’s) are a class of double stranded RNA molecules that are now known to exist as important gene regulatory factors in both plant and animal systems. Selective targeting of the androgen receptor by siRNA molecules may further silence the AR signaling pathway in prostate cancer. This may be made viable by nanoparticle technology being able to facilitate use of otherwise undeliverable agents. The development of these agents is currently hampered by the need for safe systemic delivery of these agents without the off target and immune stimulation problems encountered with other nucleic acid medicines such as plasmid DNA and anti-sense oligonucleotide [45].


4. An advanced understanding of cancer biology comes of age

4.1. Specific targeting of DNA repair mechanisms

In recent years one successful targeted approach has been to exploit the vulnerability of tumors with an impaired DNA damage repair mechanism by inhibiting a second DNA repair pathway and as such commit the cancer cell to die. This concept of synthetic lethality has been most successfully demonstrated in patients bearing tumors with BRCA-1/-2 mutations where homologous recombination (HR) mechanisms are already known to be inadequate. This hypothesis has reactivated the development of poly (ADP-ribose) polymerase (PARP) inhibitors. PARP is an enzyme that is crucial in the base excision repair pathway. When this repair mechanism is inhibited in the presence of pre-existing impaired HR then efficient DNA repair is prevented and apoptosis occurs. Following pre-clinical and more recently proof of concept clinical trials in patients with BRCA mutated breast and ovarian carcinoma, the PARP inhibitor olaparib has demonstrated significant activity [46]. Whilst it is hoped that the application of these agents may broaden to include sporadic tumours in which mutations in DNA pathways may also be found, there has also been considerable interest in other tumours types where these mutations may be found. The inherited BRCA-2 mutation is associated with a 20% lifetime risk of developing prostate cancer that often occurs before 65 years of age. The subsequent tumors are often of high Gleason score, more advanced stage at diagnosis and patients have a shorter survival than patients with sporadic prostate cancers [47]. One of three prostate cancer patients with germ-line BRCA variant had a prolonged response to olaparib in a phase 1 trial [48]. In addition to BRCA mutated cancers, pre-clinical evidence has also demonstrated a sensitivity of tumours with phosphatase and tensin homolog (PTEN) deficiency to PARP inhibition [49]. This is one of the most commonly mutated genes in human cancers where it has a role in genome stability. PTEN deficiency is associated with an HR defect that sensitizes tumours cells to PARP inhibition using the same mechanism as BRCA mutated cancers.

At present, the clinical development of olaparib has been focused on breast and ovarian cancer. Studies in prostate cancer are underway with the PARP inhibitor veliparib (or ABT888) in combination with temozolamide in a phase I study recruiting patients with metastatic prostate cancer. In addition a phase I study using the Merck PARP inhibitor - MK4827 is currently recruiting to a prostate cancer enriched second stage following encouraging phase I study data in advanced solid malignancies [50].

4.2. Oncogene addiction pathways

The development of drugs targeting tumours driven by so-called ‘oncogene addictions’ has lead to some success. Examples include imatinib targeting the bcr-abl translocation in CML and mutated c-kit in GIST, trastuzumab and laptinib in HER-2 positive breast cancers BRAF inhibitors in melanomas with BRAF mutations. Molecular studies in prostate cancer have to date identified mutations of this type in less than 20% of all sporadically occurring prostate cancers. Analysis of a cohort of 206 prostate cancer cases found the common BRAF mutation V600E in 10.2% (or 21/206 cases) [51], whilst PI3 kinase mutations were found in only 3% of a separate cohort [52]. Drugs inhibiting BRAF as well as PI3 kinase mutations may lead to meaningful responses in patients with tumors been driven by these mutations. It is hoped that further “oncogene addiction” pathways will be uncovered and be able to be drugged.

4.3. Ligand and transcription factor driven survival pathways

Whilst it is often hoped that mutations in a single molecular pathway will be uncovered as the crucial oncogenic event in tumour development and its abrogation lead to meaningful anticancer activity, to date this has been rarely found to be the case for sporadic tumours. Another approach is to consider the factors that cause and/or are associated with the development as well as the survival of cancer. The role of androgens and androgen receptor is clear for prostate cancer. Other biological approaches associated with cancer development and survival include the metabolism and inflammatory systems. In both cases, there is epidemiological, preclinical and pathological data implicating these systems in the development of prostate cancer. In comparison to the “oncogene addiction” phenomenon, these cancers are driven by altered expression of ligands and control mechanisms (such as transcription factors). Knowledge of these pathways has provided valuable clues for the treatment of cancer.


5. Targeting the metabolism system

Incidence and disease specific mortality in prostate cancer exhibit marked global variation with the highest levels seen in Western Europe, North America and the lowest in Asia [53]. It is assumed that whilst this is accounted for by a significant genetic component, that diet and lifestyle factors may also contribute. Epidemiological studies also support an association between dietary fat intake, poor prognosis and risk of relapse [54]. In order to identify new pathways that are important in prostate cancer pathogenesis, evaluating a role for the metabolism system and its key components is crucial.

Cancer cells are already known to differ from normal cells in some of the fundamental metabolic pathways they employ. Most cancer cells generate energy by primarily metabolizing glucose by glycolysis followed by lactate production. This occurs in contrast to normal cells in which glucose is catabolised by oxidative phosphorylation, a primarily aerobic process. Proliferating cancer cells also exhibit increased glucose uptake compared to normal cells. This results in tumour cells with glycolytic rates over 200 times higher than those of normal tissues and allows efficient generation of macromolecules needed for new cancer cell production. This so-called Warburg hypothesis was initially thought to be the fundamental cause of cancer, however it is now thought to explain how tumours may flourish in low oxygen environments [55]. These observations suggest that differences in metabolism between normal tissues and cancer cells may be important in oncogenesis.

Insulin and insulin-like growth factors (IGF-1) are extracellular hormones and growth factors that regulate important metabolic pathways such as fatty acid and sterol synthesis as well as growth factor signaling via the PI3 kinase and MAP kinase pathways. Their activation may stimulate tumourigenesis by activating one or both of these mitogenic pathways and disrupting fat metabolism.

IGF-I and IGF-II bind to the IGF-1 receptor, a tyrosine kinase receptor that is known to be upregulated following castration in animal models [56]. It has been implicated in the development of the castrate resistant state with evidence that inhibition of the IGF-1 receptor may enhance the effect of castration in xenograft models [57]. Targeting the IGF-1 receptor is therefore an attractive therapeutic target in CRPC. Several IGF-1 receptor inhibitors are currently being evaluated in clinical trials and candidates include both monoclonal antibodies and small molecule tyrosine kinase inhibitors. Cixutumumab (or IMC-A12) is a fully human IgG1 subclass monoclonal antibody that has reached phase II of clinical development. A single agent study of chemotherapy naïve asymptomatic patients noted that the drug was well tolerated with grade 3 fatigue and hyperglycaemia the worst toxicity seen and 29% of patients had stable disease [58]. Future trials with this agent are planned or ongoing including in the first line metastatic setting with androgen deprivation therapy (SWOG S0925) based on supporting preclinical data [57].

Drug Class Study Design Results Current phase of clinical development Reference
Insulin-like growth factor receptor inhibitors
IGF-1 R inh Phase II study in chemo naïve CRPC Asx pts
10mg/kg q2 wkly or 20mg/kg q3 wkly
29% disease stab >6 mths. Worst toxicity G3 fatigue & ↑glycaemia Phase II Neoadj +ADT in high risk pts
+ Temsiro in met CRPC
+ 1st line met+ADT
IGF-1 R inh Phase Ib in adv solid tumours in comb with docetaxel 75mg/m2 46 pts - MTD not reached. 4PR and 12 pts with disease stab >6months. G3/4 febrile neutropenia, fatigue
10/18 CRPC pts had >5 CTC with 60% response
Phase III studies recruiting in NSCLC (ADVIGO 1016). Phase II in breast, prostate, colorectal & Ewings sarcoma [59, 60]
AMG 479
IGF-1 R inh Phase I dose escalation study in adv solid malign of IV q2 wkly 53 pts - 1DLT – G3 ↓plts & transminitis. MTD not reached – maxdose 20mg/kg. ↑ in serum IGF-1 Phase II studies recruiting in Ex Stage small cell with platinum, +Everolimus in colorectal, in carcinoid & pNETs [61]
Dual kinase inhibitor of Insulin & IGF-1 R Phase I continuous dose escalation study in adv solid tumours using BID & QD dosing
Phase I intermittent dosing in adv solid tumours
57 pts – MTD reached 400mg QD, 150mg BID. DLTs were ↑ QTc & G3 hyperglycaemia
SD >12 weeks seen in 18/43 pts
MTD 600 mg
Phase III recruiting in Adrenocortical Ca
Phase II + Erlotinib in Breast
[62, 116]
AMP Kinase activators
AMP mimetic Preclinical studies show inhibition of prostate cancer cell proliferation Inhibition of tumour growth in prostate cancer xenograft models [78, 117]
A-769662 AMP K subunit act. Delay tumour development & decrease tumour incidence in PTEN def mice [79]
Metformin Indirect 44% reduction in prostate cancer cases compared to Caucasian controls Phase II recruiting in loc adv or met CRPC and in loc disease as prevention against MS with ADT [80]
Resveratrol Indirect Phase I single dose safety study in colon ca pts with hepatic metastases Results are awaited Phase I/II currently recruiting as neoadj in colon carcinoma pts [82]
mTOR inhibitors
Temsirolimus mTOR inhibitor Phase II study in CRPC patients post first line docetaxol chemotherapy. Pts receive maintenance temsirolimus 25mg/m2 weekly Currently recruiting Phase II recruiting in chemo naïve CRPC pts, in comb with cixutumumab in met CRPC, in CRPC after no response to chemo with bevacizumab & PI/II with docetaxel [118]
Everolimus mTOR inhibitor via mTORC1 Phase II study in castrate resistant prostate cancer of bicalutamide and everolimus compared to bicalutamide alone In vivo evidence of synergy between mTOR and AR pathways.
Study ongoing but 8 pts enrolled. 6/8 responses in PSA. Well tolerated with no unexpected toxicity
Phase I/II in met CRPC with docetaxel & bevacizumab, in post chemo pts with carbo/pred, in neoadj setting in int/high risk localized disease & in first line met/locally adv setting [72, 73, 74]
PI3 kinase inhibitors
XL-147 Class I PI3K isoform inhibitor Phase I dose escalation study in adv solid malig of continuous daily dosing or d1-21 of 28 day cycle 68pts – DLT G3 rash. Inhibition of PI3K & ERK demonstrated. Prolonged stable disease observed Recruiting to Phase I study in solid tumours and Phase I/II in breast & endometrial carcinoma [65]
GDC-0941 Pan PI3K inhibitor Phase I dose escalation study. GDC-0941 given QD for 21 out of 28 day cycle. BID cohorts also recruited 36 pts enrolled, dose escalation ongoing. QD dosing safe up to 254mg, BID dosing safe up to 180mg. 3 DLTs – headache, pl eff and red TLCO Phase I study recruiting in NSCLC & Met breast cancer in comb. With paclitaxel or carbo +/- bevacizumab [66]
Pan class I PI3K inhibitor Phase I dose escalation study. BKM120 PO QD 30 pts enrolled from 12.5-150mg. MTD 100mg. PD data suggests active drug at 100mg. 8/10 PR on FDG-PET Phase I/II currently accruing in HER2+ Met breast ca. Also recruiting in combination with GSK 1120212 [67]
Akt inhibitors
GSK 2141795
GSK 2110183
Akt inhibitor First-in-human phase I study of GSK 2141795 in advanced solid malig, also recruiting in combination with GSK 1120212
Perifosine Oral Akt inhibitor CRPC pts with rising PSA but no detectable mets. 900mg loading dose then 100mg daily 20% pts had a PSA reduction but did not meet PSA response criteria. DLTs included hypoNa, arthritis, photophobia, hyperuricaemia Recruiting phase III in multiple myeloma with bortezomib +/- dex , phase I in recurrent paediatric solid tumours [70]
Highly selective non ADP comp Akt inhibitor Phase I dose escalation study 30-90mg QOD in 28 day cycles in tx-refractory solid tumours MTD established at 60mg QOD. PD efficacy confirmed with dec pAKT levels. SD seen in 6/19 pts Phase II bicalutamide +/- MK2206 in pts after local therapy + rising PSA, Phase I in com with docetaxel is recruiting [71]

Table 2.

The Metabolic Syndrome

A second IGF-1 receptor antibody is the human IgG2 subclass antibody figitumumab. This was evaluated in a phase I dose escalation trial during which the maximum feasible dose was established as 20mg/kg intravenously every 21 days [59]. A phase Ib dose escalation study in combination with docetaxel then enrolled 46 predominantly metastatic CRPC patients. This combination was well tolerated with no MTD reached and the toxicity profile included nausea, febrile neutropenia, anorexia, fatigue and hyperglycaemia. A 22% response rate was observed with a disease stabilization rate of 44% for ≥ 6 months [60]. A phase II study of this combination has completed accrual and results are awaited. A third monoclonal antibody ganitumumab (or AMG478, Amgen) is also in clinical development and whilst safe in phase I dose escalation studies, its focus for ongoing development is in lung and colorectal carcinoma [61]. OSI-906 or linsitinib is a first in class inhibitor of both the insulin and IGF-1 receptors. It has been evaluated in phase I dose escalation safety studies where MTDs of 400mg QD and 150 mg BID were reached. The dose limiting toxicities were the known class effects hyperglycaemia and prolongation of the QTc interval. Whilst further development of this compound continues in adrenocortical and breast carcinomas [62], a phase II study of linsitinib in asymptomatic or mildly symptomatic CRPC patients has completed accrual and results are awaited.

An important downstream intracellular signaling pathway that has been implicated in prostate cancer pathogenesis, progression and the development of castration resistance is the PI3K/Akt/mTOR pathway. Phosphatidylinositol-3 kinase (PI3K) activation results in the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messenger phosphatidylinositol 3-5triphosphate (PIP3) that activates the Akt signal transduction cascade. Reports suggest that PI3K signaling may play a critical role in castration resistance allowing prostate cancers to maintain continued proliferation in low androgen environments [63]. In addition, the PI3K isoforms p85 and p110b appear to have a role in regulating AR-DNA interactions and the assembly of the AR based transcriptional complex [64]. There are numerous PI3K inhibitors in clinical development, XL147 (Exelixis) is a class I isoform inhibitor whilst SF1126 (Semafore), GDC0941 (Genentech) and BEZ234 (Novartis) are pan PI3K inhibitors. All agents have successfully completed phase I dose escalation studies and preliminary results suggest that these agents are well tolerated and have favourable pharmacokinetic-pharmacodynamic profiles [65 - 67]. Further tumour specific phase I/II studies are ongoing, although at present no prostate specific studies are in progress.

The Akt’s are a family of three serine/threonine kinases – AKT-1, AKT-2, & AKT-3. Phosphorylation of AKT modulates multiple downstream cellular functions including apoptosis, metabolism and proliferation. Enhanced pAKT correlates with more aggressive histological and pathological prostate cancer stage, and a worse prognosis underlining its importance as a druggable target and possible role as a prognostic biomarker [68, 69]. There are several classes of Akt inhibitors currently in clinical development including those inhibiting the catalytic and the pleckstrin homology (PH) domains. Perifosine, an alkylphospholipid inhibiting the PH domain has reached phase II in CRPC patients. Unfortunately although well tolerated this agent did not exhibit significant activity [70]. The pan-AKT inhibitors GSK2141795 and MK2206 with simultaneous targeting of both AKT-1 and AKT-2 are considered potentially superior to single isoform inhibitors. MK2206 was well tolerated in a phase II dose escalation study with an observed MTD of 60mg. Pharmacodynamic endpoints were met with a measurable reduction in pAKT levels. In addition, 6 of 19 patients achieved stable disease [71]. Further development continues in a number of tumour types both as single agent and in combination with chemotherapy. Of note a phase I study in combination with docetaxel is currently recruiting, as is a randomized phase II study of bicalutamide +/- MK2206 in prostate cancer patients with a rising PSA after definitive local therapy. GSK2141795 and GSK 2110183 also entered phase I development with results of first in human safety studies pending.

Mammalian target of rapamycin (mTOR) is also a serine/threonine kinase downstream of PI3K which interacts with the mTOR complexes mTORC1 and mTORC2 to regulate cell proliferation and inhibit apoptosis. Proof of principle that the PI3K pathway can be successfully targeted for clinical use in cancer has been demonstrated by the development of the rapamycin analogs - temsirolimus and everolimus that inhibit the mTORC1 kinase. Temsirolimus is an intravenous formulation which was the first compound in this class to be approved by the FDA for first line treatment in poor risk patients with advanced renal cell cancer. Everolimus an oral formulation is also approved for use in advanced renal cell cancer but in the second line setting. Single agent studies of these agents in the prostate cancer setting have been performed but were considered disappointing with a short time to progression (2.5 months) and no radiographic or PSA responses [72]. Everolimus has also been evaluated in combination with docetaxel in CRPC patients. The recommended phase II dose was 10mg everolimus and 70mg/m2 docetaxel, 3 patients had a PSA response and the combination was well tolerated with fatigue and haematological toxicities the most common [73]. Further studies with both agents in prostate cancer continue with a similar study involving temsirolimus in combination with docetaxel, as well as studies with cixitumumab and bevacizumab. A randomized study in hormone responsive patients of bicalutamide +/- everolimus is currently recruiting with early results suggesting the combination was well tolerated with PSA responses observed in six of eight patients [74]. Studies in the neoadjuvant and localized disease setting are also ongoing.

Finally, AMP kinase is a serine/threonine kinase that is activated by metabolic stressors that deplete ATP and increase AMP levels. Its activity is also under the control of hormones such as adiponectin and leptin as well as cytokines [75]. The activation of AMP kinase reduces insulin levels, as well as increasing ATP producing activities (glucose uptake, fatty acid oxidation) and suppressing ATP-consumption (synthesis of fatty acids, sterols, glycogen and proteins). AMP kinase therefore acts as a metabolic switch controlling glucose and lipid metabolism. Decreased AMP kinase activity is thought to contribute to the metabolic abnormalities involved in the metabolic syndrome [76]. In addition polymorphisms in a gene locus encoding one of the AMPK subunits correlates with prostate cancer risk [77].

Activators of AMP kinase activity may be direct or indirect. Several direct AMP kinase activators act either by allosteric binding to AMP kinase subunits or as an AMP mimetic. These agents aminoimidazole-4-caboxamide-1-b-riboside (AICAR), A-769662 and PT1 are at an early stage of clinical development. AICAR has been shown to inhibit prostate cancer cell proliferation and tumour growth in xenograft models [78]. However its further development may be limited by its poor specificity for AMPK and low oral bioavailability. To date no interventional oncology studies have been undertaken. The recent publication of the crystal structure of AMP kinase subunits has allowed rational drug design of A-769662 and PT1. A769662 has been shown to delay tumour development and decrease tumour incidence in PTEN deficient mice [79].

The indirect activator metformin is a well established treatment for type II diabetes mellitus. Its use is associated with a 44% risk reduction in prostate cancer cases compared with controls in Caucasian men [80]. The mechanism of metformin’s antitumour effect is not completely understood, although it is hypothesized that metformin may decrease circulating glucose, insulin and IGF-1 levels by inhibiting hepatic gluconeogenesis resulting in increased signaling through the insulin/IGF-1 pathway [81]. Its action in prostate cancer is currently under evaluation in a number of clinical trials, these include as a preventative treatment for metabolic syndrome in men on androgen deprivation therapy and as first line therapy in locally advanced or metastatic prostate cancer patients. Finally, resveratrol is a phytoalexin produced by plants when under attack by pathogens. It is found in the skin of grapes, grape products, red wine and mulberries and is thought to have anticancer properties. These were first identified when it was shown to inhibit tumourigenesis in a mouse skin cancer model [82]. Its indirect action on AMP kinase remains to be elucidated although its anticancer action has been explored in a number of tumour types. Clinical trials using resveratrol have explored potential roles in preventing and treating diabetes, Alzheimers disease and weight loss. In addition safety studies of its use in colorectal carcinoma patients with liver metastases have been conducted and the results are awaited. As yet no studies in prostate cancer are planned.


6. Inflammation

Numerous studies have implicated inflammation in the development of prostate cancer and its metastases. Pathologists have recognized focal areas of epithelial atrophy in the periphery of the prostate (proliferative inflammatory atrophy - PIA), where prostate cancers typically arise and these areas are associated with acute or chronic inflammation and can show morphological transitions in continuity with high grade PIN [83]. This could indicate a role of PIA as a cancer precursor [84]. Putative causes of these lesions are infection or dietary oxidants. To date, the identification of an infectious agent directly involved in prostate carcinogenesis has been elusive. However, it is possible that one or more infectious agents may be indirectly involved in prostate carcinogenesis by being initiators of the inflammatory lesion (PIA). Interesting data includes serologic evidence of T. vaginalis infection being associated with a higher prostate cancer risk overall, and an almost two-fold risk for poorly differentiated disease [85] as well as greater prostate cancer specific mortality (HR: 1.5; 95% CI: 1.0, 2.2) [86]. It is also of note that hereditary susceptibility genes which encode proteins with infectious response function: RNASEL and MSR1 (macrophage scavenger receptor 1) have been associated with prostate cancer [83]. Single nucleotide polymorphism’s of anti-oxidant genes have also been associated with prostate cancer and include OGG1 (repair from oxidized DNA), MnSOD [88]. Also the incidence of prostate cancer has been decreased with anti-oxidants such as lycopene and NSAIDs [87].

One possible mediator of the inflammation that leads to cancer and is instigated by oxidative stress from a diverse arrays of causes is NFκB activation. Specifically, it has been shown that a vicious cycle of oxidative stress causing DNA damage and consequent influx of inflammatory cytokines into the microenvironment results in further production of proteases, angiogenic factors, growth factors and immunosuppressive cytokines. Examples of NFκB controlled proteins found in prostate cancer include COX-2, XIAP, CXCR4, macrophage inhibitory cytokine-1 (MIC-1), IL-6, IL-8, IL-1, CXCL12, and the CXCR4 [89].

NFκB is a protein complex that controls DNA transcription and is activated by numerous factors including cytokines, free radicals, receptor activator of nuclear factor kappa-B (RANK), and microbial pathogens [90]. Upon activation, the NFκB dimers translocate to the nucleus with activation of numerous genes controlling cell growth, differentiation, inflammatory responses and apoptosis. Aberrant regulation of NFkB has previously been linked to inflammatory states and cancer. Moreover, NFκB controls many of the hallmarks of cancer including: invasion (IL-6); angiogenesis (IL-8, VEGF); propagation through the cell cycle (cyclin D1); and evasion of apoptosis (cIAP-1, TRAF-2, Bcl-XL) [91 - 95]. As such, NFκB activation has clear-cut biological plausibility as a driver of cancer progression and CRPC. In tumor cells, NFκB is constitutively active either due to mutations in genes encoding the NFκB transcription factors themselves or in genes that control NFκB activity (such as IκB genes) or due to tumor cells secreting activation factors (e.g. IL-1). Constitutive NFκB activation in prostate cancer is found in both tumor and its associated stroma and occurs early in the disease process [96 - 100]. It is of note that preclinical work has mechanistically connected NFκB activation to development of prostate cancer with a metastatic phenotype [97]. Specifically, loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP lead to increased EZH2 and in turn induced NFκB activation which in turn resulted in metastatic prostate cancer in an orthotopic mouse tumor model.

Drugs targeting the inflammatory system are in preclinical and clinical development. The agents can be classified as upstream or direct inhibitors of nuclear factor kappa B or inhibitors of products of NFκB activation Table 3. This is a very new area but one which may lead to significant improvements.

Drug Class Study Design Results Current phase of clinical development Reference
Upstream agents
(Enhancer of Zeste protein)
Polycomb grp protein
Pre-clinical studies only
Ectopic expression of miRNAs impt in EZH2 action inhibit cell growth & tumourigenesis
Randomised phase II in mCRPC with PD on or within 6m docetaxel (D)
D/Pred/C or Mito/Pred/C
42 pts – 3/23pts with PR in
D/P/C OS 15.8 mths M/P/C OS 11.5 mths
Toxicity similar in both arms
Phase III Docetaxel +/- Custirsen in mCRPC as 1st & 2nd line recruiting [120]
Phase II study of bortezomib with addition of MAB on progression. Bortezomib given d1,4,8,11 for 3 cycles No activity in addition to docetaxel or paclitaxel (phase I) and high rates of PN observed. When given as single agent or MAB – 11/15 CR with TTP 5.5 months
Results awaited for phase I study with mitoxanthrone [121, 122, 123]
Selective proteosome
Phase I trial in relapsed or refractory haem malig, d1-5 IV 1.2-20mg/m2 MTD 15mg/m2 – DLT of feb neutropenia & G4 thrombocytopenia. 2/29 responses No prostate specific trials recruiting [124]
Anti-RANKL antibody Randomised phase III trial denosumab vs zoledronic acid in mCRPC with bone mets
Median time to first SRE 20.7m denosumab vs 17.1m zoledronic acid HR 0.82 p=0.00002 Phase III study investigating lens opacification in men on demosumab and ADT [125]
Direct agents
(derived from Milk Thistle)
Via down regulation of epithelial-mesenchymal transition regulators Phase II single arm study in PC pts with localized disease prior to prostatectomy. Pts given 13g/day Transient high blood concentration observed but low tissue concentration. Response results awaited [126]
Cyclin dependent kinase inhibitor Phase II single agent study in met CRPC pts.
72 hour IV infusion at 40-60 mg/m2/day
36 pts enrolled. No objective responses. 14% pts met 6 month PFS endpoint. Further development in germ cell tumours & gastric/GOJ ca [127]
Thalidomide IκB kinase inhibitor Phase II studies docetaxel (75mg/m2) and docetaxel/bevacizumab (15mg/m2) +/- thalidomide (200mg/m2) 60 pts enrolled. 90% PSA decline of >50%. Median TTP 18.3 months, median OS 28.2 months. Manageable toxicity but all pts had G3/4 neutropenia Phase III placebo controlled trial in recurrent hormone sensitive non metastatic PC [128, 129]
Lenolidamide Phase II trial after biochemical relapse with LHRH agonists & phase I/II trial as single agent 5mg or 25 mg 159 pts enrolled. Med TTP PSA 15 vs 9.6 mths. Thalidomide well tolerated, 47% DR. 60 pts enrolled, 25mg ass with greater change in PSA slope but higher toxicity Phase III in met CRPC pts, docetaxel/prednisone +/- lenolidamide [130, 131]
(derived from
Tanacetum parthenium)
NFκB inhibitor Dimethylamino-partehnolide (DAMPT) with superior solubility & bioavailability DAMPT inhibited NFkB DNA binding & expression of NFkB regulated anti-apoptotic proteins Phase I dose escalation trial currently recruiting in pts with haem malig [132]
Downstream agents
αIL-6 Ab
Phase II study in met CRPC pts post docetaxel. 6mg/kg IV q14d for 12 cycles 53 pts enrolled. PSA response rate 3.8%, RECIST SD rate 23%. High baseline IL-6 levels ass with poor prognosis Phase I study in combination with docetaxel in met CRPC pts [133]
α-chemokine ligand 2 Ab
Preclinical studies of CNTO888 2mg/kg twice weekly ip in vivo prostate cancer model Reduced tumour burden by 96% at 5 weeks also synergistic with docetaxel Phase II in met CRPC pts post docetaxel results awaited [134]
Focus of clinical dvpt in AML, phase I/II studies recruiting

Table 3.

The Inflammatory System


7. Other key pathways

With time, it is anticipated that more pathways and targets key to prostate cancer growth will be identified. Angiogenesis inhibition has been successful in other cancers but minimal activity was seen in trials with Sunitinib [101] and Bevacizumab [102]. Similarly, targeting the HGF-MET axis is supported by preclinical work [103] and some activity has been seen with MET inhibition. However, Cabozantinib – a tyrosine kinase inhibitor that inhibits multiple receptor tyrosine kinases (RTKs) with growth-promoting and angiogenic properties (MET (IC50 in enzymatic assays= 1.8nM), VEGFR2 (0.035nM), RET (3.8nM), and KIT (4.6nM) has significant and intriguing clinical activity in bony disease and some activity in soft tissue disease. This suggests the effect may be due to concurrent inhibition of two relevant pathways.

Cabozantinib has been studied in multiple solid tumors and has shown a broad spectrum of activity with tumour regression in patients with a variety of diseases. It’s activity in medullary thyroid cancer is based on RET inhibition [104]. Of particular relevance to prostate cancer, a phase II discontinuation study of 168 men with progressive metastatic CRPC received Cabozantinib initially for 12 weeks [105]. Patients with PR continued open-label cabozantinib, patients with stable disease were randomized to cabozantinib or placebo, whilst patients with progression were discontinued. Trial accrual was halted after enrollment of 168 patients due to the significant activity observed. 78% patients had bone metastasis and significantly 86% of these had a complete or partial response on bone scan as early as week 6. 64% patients had improved pain and 46% patients reported lower narcotic analgesia use. To date the median PFS has not been reached. Most common related Grade 3/4 AEs were fatigue (11%), HTN (7%), and hand-foot syndrome (5%). Osteoclast and osteoblast effects were observed: 55% had declines of ≥50% in plasma C-Telopeptide; 56% of patients with elevated tALP had declines of ≥50%.

Interestingly numerous lines of preclinical and clinical evidence implicate MET and VEGFR activation in bone metastases as well as prostate cancer, especially castration resistant disease. Specifically, androgen deprivation increases MET expression in prostate cancer cells [106, 107] and c-met has been shown to be upregulated in CRPC and may be a factor that supports CRPC cells in the castrate state [106, 108]. Androgen deprivation also increases expression of c-met’s ligand, Hepatocyte Growth Factor (HGF) in the stroma. Increased expression of MET and HGF may contribute to disease progression following androgen deprivation therapy. This may be a compensatory mechanism as HGF/cMET activity enhances Leydig cell steroidogenetic activity [109]. It is also of note that increased expression of MET and/or HGF correlate with prostate cancer metastasis and disease recurrence [110, 111]. In addition, VEGF has been shown to activate MET signaling via neuropilin-1. Osteoblasts and osteoclasts also express MET and VEGFRs and osteoclasts secrete HGF. This supports the notion that MET signaling not only supports the tumor, but also bone turnover which provides a fertile microenvironment for prostate cancer growth [112]. These observations provide a strong rationale for dual inhibition of VEGFR2 and MET as a therapeutic strategy in men with CRPC and bone metastases. As such, cabozantinib may not only have single agent activity but also enhance abiraterone activity by simultaneously blocking a putative resistance/survival mechanism to hormonal therapy and abrogating bone turnover and making the microenvironment less hospitable for cancer growth. Given these many reasons, it is logical to hypothesize that combining these two active agents against CRPC will result in even more substantial clinical benefit.


8. Conclusion & future directions

It is clear from the foregoing discussion that increased biological knowledge and drug development technologies has resulted in a vast number of agents for clinical trial testing. However, it is paramount that judicious trial designs are employed and match the drug to the tumor by ensuring that the target is present. It is also quite certain that no single drug will work given the inherent multiple redundant survival pathways. This is probably more apparent for castration resistant disease. Therefore, one can argue that waiting for metastatic disease or castrate resistant disease to assess a new drug is a defeatist approach, and that an assessment earlier in the disease spectrum to prevent the emergence of resistance is a more proactive and promising approach to improve outcomes in prostate cancer. The conduct of a study in patients with a biochemical relapse after definitive localized therapy provides a major opportunity for drug development. This approach allows the analysis of a drug in isolation and as well as an assessment and effective triage of the numerous new agents that are now available for testing. Also the primary pathology can be interrogated to look for activation of the pathway and provides an opportunity to biologically direct the evaluation of drugs relevant to a given a pathway in an individual’s cancer. Ultimately, key combinations simultaneously targeting the essential and multiply redundant pathways driving cancer survival and resistance mechanisms can be developed. This has been a successful strategy for treatment of HIV and AIDS where the early use of Highly Active Anti-retroviral Therapy (HAART) has made major advances. With time and judicious clinical development, it is possible to develop a similar strategy such as Highly Effective Early Prostate Cancer Therapy (HEEPT) for patients with rapidly progressive PSA rises after definitive local therapy and have a long life expectancy. Early use of a highly effective combination therapy will hopefully eradicate the disease and prevent patients from dying from recurrent disease that may otherwise have been lethal and more difficult to treat if waited until later in the disease


  1. 1. Sridhara R, Johnson J R, Justice R et al: Review of oncology and haematology drug product approvals at the US Food and drug administration between July 2005 and December 2007. J Natl Cancer Inst 2010 102(8) 578-9
  2. 2. Lo Russo P M, Anderson A B, Boerner S A et al. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? Clin Cancer Res 2010 16(24) 5956-62
  3. 3. Tannock IF, Osoba D, Stockler MR et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end-points. J Clin Oncol 1996 14(6) 1756-64
  4. 4. Tannock I F, de Wit R, Berry WR et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351 1502-12 2004
  5. 5. Morris PG & Fornier MN: Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008 14 7167-7172
  6. 6. De Bono J S, Oudard S, Ozguroglu M et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castrate resistant prostate cancer progressing after docetaxel treatment: a randomized open label trial. Lancet 2010 376 (9747) 1147-54
  7. 7. Gradishar WJ, Tjulandin S, Davidson N et al: Phase III trial of nanoparticle bound paclitaxel with polyethylated castor oil based paclitaxel in women with breast cancer. J Clin Oncol 2005 23(31) 7794-803
  8. 8. Mita M, Mita A, Sarantopoulos J et al: Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies. Cancer Chemother Pharmacol 2009 64(2) 287-295
  9. 9. Beer TM, Ryan C, Alumkal J et al: A phase II study of paclitaxel poliglumex in combination with transdermal oestradiol for the treatment of metastatic castrate resistant prostate cancer after docetaxel chemotherapy. Anticancer drugs 2010 21(4) 433-438
  10. 10. Farokhzad OC, Cheng J, Teply BA et al: Targeted nanoparticle aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006 103(16) 6315-6320
  11. 11. Liu G, Chen YH, Dipaola R et al: Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the eastern co-operative oncology group. Clin Genitourin Cancer 2012 10(2) 99-105
  12. 12. Chi KN, Beardsley E, Eigl BJ et al: A phase II study of patupilone in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology group study P07a. Ann Oncol 2012 23(1) 53-58
  13. 13. Beer TM, Smith DC, Hussain A et al: Phase II study of sagopilone plus prednisone in patients with castrate-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer 2012 doi 10.1038/bjc.2012.339
  14. 14. De Bono J S, Molife R, Sonpavde G et al: Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol 2012 23(5) 1241-1249
  15. 15. Nilsson S, Parker C, Haugen I et al: Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined analyses of phase I and II clinical trials. 2010 Genitourinary cancer symposium abstract 106
  16. 16. Sartor AO, Heinrich D, O’Sullivan JM et al: Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA). J Clin Oncol 2012 30 suppl abstrc 4551
  17. 17. Huggins C & Hodges CV. Studies on prostate cancer, I: the effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941 1 293-297
  18. 18. Craft, N, Shostak Y, Carey M et al: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 1999 5 280–285
  19. 19. Gioeli, D, Ficarro SB, Kwiek JJ et al: Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem. 2003 277 29304–29314
  20. 20. Veldscholte, J Ris-Stalpers C, Kuiper GG et al: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 1990 173 534–540
  21. 21. Chen CD, Welsbie DS, Tran C et al: Molecular determinants of resistance to anti-androgen therapy. Nature Medicine 2004 10 (1) 33-39
  22. 22. Mitsiades N, Schultz B, Taylor S et al: Increased expression of androgen receptor and enzymes involved in androgen synthesis in metastatic prostate cancer: targets for novel personalized therapies. J Clin Oncol 2009 27: (15 suppl) abstr 5002
  23. 23. Koivisto PA & Hellin H J: Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. Am J Pathol 1999 189(2) 219-223
  24. 24. Mohler JL, Gregory CW, Ford OH. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004 10 440-448
  25. 25. Figg WD, Liu Y, Arlen P et al. A randomized phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005 173 790-796
  26. 26. Attard G, Reid A H M, A’Hern R et al: Selective inhibition with Cyp 17 with abiraterone acetate is highly active in the treatment of castrate-resistant prostate cancer. J Clin Oncol 2010 27 (23) 3742-3748
  27. 27. Reid AH, Attard G, Danila DC et al. Significant and sustained anti-tumour activity in post docetaxel castration resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010 28 1489-1495
  28. 28. De Bono JS, Logothetis CJ, Molina A et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 364(21) 1995-2005
  29. 29. Ryan CJ, Smith MR, De Bono JS et al: Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012 suppl. Abstrc LBA 4518
  30. 30. Petrylak DP, Gandhi JG, Clark WR et al: Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012 30 suppl abstrc 4656
  31. 31. Dreicer R, Agus DB, Bellmunt J et al: A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. J Clin Oncol 2012 20 suppl abstrc TPS4963
  32. 32. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009 10 981-991
  33. 33. Scher HI, Beer TM, Higano CS et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010 375 (9724) 1437-1446
  34. 34. De Bono JS, Fizazi K, Saad F et al: Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol 2012 30 suppl abstrc 4519
  35. 35. Bolden JE, Peaert MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 5 769-784
  36. 36. Welsbie DS, Xu J, Chen H et al: Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate – resistant prostate cancer. Cancer Res 2009 69 958-966
  37. 37. Rathkopf D, Wong BY, Ross RW et al: A phase I study or oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 2010 66 (1) 181-9
  38. 38. Bradley D, Rathkopf D, Dunn R et al: Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009 115 (23) 5541-9
  39. 39. Schneider BJ, Kalemkerian GP, Bradley D et al. Phase I study of vorinostat in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs 2012 30(1) 249-257
  40. 40. Powers MV, Workman P: Targeting of multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006 13 (Suppl 1): S125-S135
  41. 41. Solit DB, Egorin M, Valentin G et al: Phase I pharmacokinetic and pharmacodynamic trial of docetaxel and 17-AAG (17-allylamino-17-demethoxygeldanamycin). J Clin Oncol 2004 22 (14 Suppl) Abstr 3032
  42. 42. Heath EI, Hillman DW, Vaishampayam U et al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008 14 (23) 7940-7946
  43. 43. Oh W, Stadler WM. Srinivas S et al: A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC). Presented at ASCO Genitourinary symposium 2009 Abstract 219
  44. 44. Goldman JW, Raju RN, Gordon GA et al: A Phase 1 dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. J Clin Oncol 2010 28:15s (suppl; abstr 2529)
  45. 45. Oh Y K & Park T G. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009 61(10) 850-862
  46. 46. Tutt A, Robson M, Garber J E et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof of concept trial. Lancet 2010 376 235-244
  47. 47. Gallagher DJ, Gaudet MM, Pal P et al: Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010 16 (7) 2115-21
  48. 48. Fong PC, Boss DS, Yap TA et al: Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutations carriers. N Engl J Med 2009 361 123-134
  49. 49. Mendes-Pereira AM, Martin SA, Brough R et al: Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009 1 (6-7) 315-22
  50. 50. Sandhu SK, Wenham RM, Wilding G et al: First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. J Clin Oncol 28:15s 2010 (suppl abstr 3001)
  51. 51. Cho N Y, Choi M, Kim B H et al: Braf and Kras mutations in prostatic adenocarcinoma. Int J Cancer 2006 119(8) 1858-62
  52. 52. Sun X, Huang J, Homma T et al: Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res 2009 29(5) 1739-43
  53. 53. Hsing A W & Devesa S S: Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001 23 3-13
  54. 54. Strom S S, Yamamura Y, Forman MR et al: Saturated fat intake predicts biochemical failure after prostatectomy. Int J Cancer 2008 122 2581-5
  55. 55. Warburg O. On the origin of cancer cells. Science 1956 123 309-314
  56. 56. Nickerson T, Pollak M Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology 1998 139(2) 807-810
  57. 57. Plymate S R, Haugk K, Coleman I et al: An antibody targeting the type I insulin-like growth factors receptor enhances the castration induced response in androgen-dependent prostate cancer. Clin Can Res 2007 13(21) 6429-39
  58. 58. Higano CS, Alumkal JJ, Ryan CJ et al: A phase II study of cixutumumab (IMC-A12), a monoclonal antibody (MAb) against the insulin-like growth factor 1 receptor (IGF-IR), monotherapy in metastatic castration-resistant prostate cancer (mCRPC): Feasibility of every 3-week dosing and updated results. Presented at the ASCO Genitourinary Symposium 2010 Abstract 189
  59. 59. Haluska P, Shaw H M, Batzel G N et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumours. Clin Cancer Res 2007 13 5834-55840
  60. 60. Molife LR, Fong PC, Pacagnella L et al: The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751, 871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 2010 103 (3) 332-9
  61. 61. Tolcher AW, Sarantopoulos J, Patnaik A et al: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009 27 (34) 5800-7
  62. 62. Carden CP, Lim ES, Jones RL et al: Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors. J Clin Oncol 2010 28:15s (suppl; abstr 2530)
  63. 63. Mulholland DJ, Dedhar S, Wu H et al: PTEN & GSK3beta: key regulators of progression to androgen-independent prostate cancer. Oncogene 2006 25(3) 329-337
  64. 64. Jia S, Liu Z, Zhang S et al: Essential roles of PI(3)K-p110bin cell growth, metabolism and tumourigenesis. Nature 2008 454 776-9
  65. 65. Edelmann G, Bedell C, Shapiro G et al: A phase I dose escalation study of XL147 (SAR205408), a PI3K inhibitor administered orally to patients with advanced malignancies. J Clin Oncol 2010 28 15s (suppl;abstrc 3004)
  66. 66. Von Hoff DD, LoRusso P, Tibes R et al: A first in human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours. J Clin Oncol 2010 28:15s (suppl;abstr 2541)
  67. 67. Baselga J, De Jonge MJ, Rodon J et al: A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumours. J Clin Oncol 28:15s 2010 (suppl;abstr 3003)
  68. 68. Kreisberg J I, Malik S N, Prihoda T J et al: Phosphorylation of Akt (ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004 64 5232-5236
  69. 69. Ayala G, Thompson t, Yang G et al: High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004 10 6572-6578
  70. 70. Chee K G, Longmate J, Quinn D I et al: The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007 5(7) 433-7
  71. 71. Tolcher AW, Yap TA, Fearen I et al: A phase I study of MK-2206, an oral potent allosteric Akt inhibitor in patients with advanced solid tumours. J Clin Oncol 2009 27 15s (suppl;abstrc 3503)
  72. 72. George D J, Armstrong A J, Creel P: A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC). ASCO Genitourinary Cancers Symposium 2008: abstract 181
  73. 73. Ross R W, Manola J, Oh W K et al: Phase I trial of RAD001 and docetaxel in castration resistant prostate cancer with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008 26 abstrc 5069
  74. 74. Pan C, Ghosh P, Lara P et al: Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial. J Clin Oncol 2011 suppl. 11 abstrc 157
  75. 75. Hardie D G. AMP-activated/SNF-1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007 8 774-785
  76. 76. Luo Z, Saha AK, Xiang X et al: AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005 26 69-76
  77. 77. Matsui H, Suzuki K, Ohtake N et al: Genome wide linkage analysis of familial prostate cancer in the Japanese population. J Hum Genet 2004 49 9-15
  78. 78. Xiang X, Saha A K, Wen R et al: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004 321 161-7
  79. 79. Huang X, Wullschleger S, Shapiro N et al: Important role of the LKB1-AMPK pathways in suppressing tumourigenesis in PTEN-deficient mice. Biochem J 2008 412 212-21
  80. 80. Wright J L & Stanford J L: Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009 20 1617-22
  81. 81. Pollak M: Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008 8 915-28
  82. 82. Jang M, Cai L, Udeani G O et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997 275 218-220
  83. 83. De Marzo AM, De Weese TM, Platz EA et al: Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention and treatment. J Cell Biochem 2004 91 459-477
  84. 84. De Marzo AM, Marchi VL, Epstein JI & Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostate carcinogenesis. Am J Pathol. 1999 59 (22) 1985-1992
  85. 85. Sutcliffe S, Giovanucci E, Alderete JF et al: Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006 15(11) 939-945
  86. 86. Stark JR, Judson G, Alderete JF et al: Prospective study of Trichomonas vaginaslis infection and prostate cancer incidence and mortality: Physicians health study. J Natl Cancer Inst 2009 101 (20) 1406-1411
  87. 87. Nelson WG, De Marzo AM, Isaacs WB et al: Mechanisms of disease: prostate cancer. N Engl J Med 2003 349 366-381
  88. 88. Li H, Kantoff PW, Giovanucci E et al: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status and risk of clinically significant prostate cancer. Cancer Res 2005 65(6) 2498-2504
  89. 89. Dobrovolskaia MA & Kozlov SV: Inflammation & Cancer:when NFκB amalgamates the perilous partnership. Curr Cancer Drug Targets 2005 5(5) 325-344
  90. 90. Ghosh S, Bhattacharya S, Sirkar M et al: Leishmania donovani suppresses activated protein1 and NF-κB activation in host macrophages via ceramide generation: involovement of extracellular signal-regulated kinase Infect Immun 2002 70(12) 6828-6838
  91. 91. Helbig G, Christopherson KW, Bhat-Nakshatri P et al: NK-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003 278(24) 21631-21638
  92. 92. Zong WX, Edelstein LC, Chen C et al: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNF alpha induced apoptosis. Genes Dev 1999 13 (4) 382-387
  93. 93. Dolcet X, Llobet D, Pallares J et al: NF-kB in development and progression of human cancer.Virchows Archiv 2005 446 (5) 475-482
  94. 94. Wang CY, Mayo MW, Baldwin AS: TNF and cancer therapy-induced apoptosis: potentation by inhibition of NF-κB. Science 1996 274: 784-787
  95. 95. Karashima T, Sweeney P, Kamat A et al: Nuclear factor κB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003 9(7) 2786-2797
  96. 96. Ammirante M, Luo JL, Grivennikov S et al: B-cell derived lymphotoxin promotes castration resistant prostate cancer. Nature 2010 464 302-5
  97. 97. Min J, Zaslavsky A, Fedele G et al: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nat Med 2010 16(3) 286-294
  98. 98. Sweeney C, Li L, Shanmugam R et al: Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004 10(16) 5501-5507
  99. 99. Lessard L, Begin LR, Gleave ME et al: Nuclear localization of nuclear factor-κB transcription factors in prostate cancer: an immunohistochemical study 2005 93(9) 1019-1023
  100. 100. Lessard L, Mes-Masson AM, Lamarre L et al. NF κB nuclear localization and its prognostic significant in prostate cancer BJU Int. 2003 91(4) 417-420
  101. 101. Michaelson MD, Oudard S, Ou Y et al: Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011 29 suppl abstrc 4515
  102. 102. Heidenreich A, Pfister DJ, Thüer D et al: Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following first-line docetaxel. J Clin Oncol 2010 28 suppl abstrc e15006
  103. 103. Varkaris A, Corn PG, Gaur S et al: The role of HGF/c-met signaling in prostate cancer progression and c-met inhibitors in clinical trials. Exp Opin Investig Drugs 2011 20 (12) 1677-84
  104. 104. Kurzrock R, Sherman SI, Ball DW et al: Activity of XL-184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011 29 2660-2666
  105. 105. Hussain M, Sweeney C, Corn PG et al: Cabozantanib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 2011 29 (Suppl) abstrc 4516
  106. 106. Humphrey PA, Zhu X, Zarnegar R et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol. 1995 147 (2) 386-396
  107. 107. Verras M, Lee J, Xue H et al: the androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007 67 (3) 967-975
  108. 108. Tu WH, Zhu C, Clark C et al: Efficacy of c-Met inhibitor fpr advanced prostate cancer. BMC Cancer 2010 10 556
  109. 109. Del Bravo J, Catizone A, Ricci G et al: Hepatocyte growth factor-modulated rat Leydig cell functions. J Androl. 2007 28(6) 866-874
  110. 110. Knudsen BS, Gmyrek GA, Inra J et al: High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002 60(6) 1113-1117
  111. 111. Humphrey PA, Halabi S, Picus J et al: Prognostic significance of plasma scatter/hepatocyte growth factor levels in patients with metastatic hormone refractory prostate cancer: results from Cancer & Leukaemia group B 150005/9480. Clin Genitourin Cancer 2006 4(4) 269-274
  112. 112. Grano M, Galimi F, Zambonin G et al: Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proceedings of the National Academy of Sciences of the United States of America. 1996 93(15) 7644-7648
  113. 113. Bruno RD, Vasaitis TS, Gediya LK et al: Synthesis and biological evaluations of putative metabolic stable analogs of TOK-001: head to head anti-tumour efficacy evaluation of TOK-001 and Abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids 2011 76(12) 1268-1279
  114. 114. Yong W, Goh B, Toh H et al: Phase I study of SB939 three times weekly for 3 weeks every 4 weeks in patients with advanced solid malignancies. J Clin Oncol 27:15s, 2009 (suppl; abstr 2560)
  115. 115. Molife LR, Attard G, Fong PC et al: Phase II, two-stage, single arm trial of the histone deacetylase inhibitor (HDAC) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010 21: 109-113
  116. 116. Evans T, Lindsay CR, Chan E et al: Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2531).
  117. 117. Ben Sahra I, Laurent K, Loubat A et al: The antidiabetic drug metformin exerts an anti-tumoural effect in vitro and in vivo through a decrease in cyclin D1 level. Oncogene 2008 27 2576-3586
  118. 118. Emmenegger U, Berry SR, Booth C et al: Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). J Clin Oncol 2011 29 Suppl 7 Abstrc 160
  119. 119. Lu J, Me ML, Wang L et al: MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2.Cancer Res 2011 71(1) 225-233
  120. 120. Saad F, Hotte S, North S et al: Randomized Phase 2 Trial of Custirsen (OGX-011) with Docetaxel or Mitoxantrone in Patients with Metastatic Castrate-Resistant Prostate Cancer: CUOG Trial P06c. Clin Cancer Res 2011 Epub ahead of print.
  121. 121. Hainsworth JD, Meluch AA, Spigel DR et al; Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitorurin Cancer 2007 5(4) 278-283
  122. 122. Cresta S Cessa C, Catapano CV et al: Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 2008 44 (13) 1829-1834
  123. 123. Kraft AS, Garrett-Mayer E, Wahlquist AE et al: Combination therapy of recurrent prostate cancer with the proteosome inhibitor Bortezomib plus hormone blockade. Cancer Biol Ther 2011 12(2) 119-124
  124. 124. O’Connor OA, Stewart AK, Vallone M et al: A phase I dose escalation study of the safety and pharmacokinetics of the novel proteosome inhibitor carfilzomib in patients with haematological malignancies. Clin Cancer Res 15 (22) 7085-91
  125. 125. Fizazi K, Carducci M, Smith M et al: Denosumab versus zoledronic acid for treatment of bone metastases in men with castrate-resistant prostate cancer: a randomized double blind study. Lancet 2011 377 813-822
  126. 126. Flaig TW, Glode M, Gustafson D et al: A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010 70(8) 848-855
  127. 127. Liu G, Gandara DR, Lara PN et al: A phase II trial of flavopiridol in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004 10(3) 924-928
  128. 128. Ning Y-M, Gulley JL, Arlen PM et al: Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration resistant prostate cancer. J Clin Oncol 2010 28(12) 2070-2076
  129. 129. Dahut WL, Gulley JL, Arlen PM et al: Randomised phase II trial of docetaxel plus thalidominde in androgen-independent prostate cancer. J Clin Oncol 2004 22 2532-2539
  130. 130. Figg WD, Huassain MH, Gulley JL et al: A double blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol 2009 181(3) 1104-1113
  131. 131. Keizman D, Zahurak M, Sinibaldi V et al: Lenolidamide in non-metastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded randomized study. Clin Cancer Res 2010 16(21) 5269-5276
  132. 132. Shanmugam R, Kusumanchi P, Cheng L et al: A water soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkB & generating reactive oxygen species. Prostate 2010 70(10) 1074-1086
  133. 133. Dorff TB, Goldman B, Pinski JB et al: Clinical and correlative results of SWOG S0354: a phase II trial of CNTO 328 (Siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy pre-treated patients with castration resistant prostate cancer. Clin Cancer Res 2010 16(11) 3028-3034
  134. 134. Loberg RD, Ying C, Craig M et al: Targeting CCL-2 with systemic delivery of neutralizing antibodies induced prostate cancer tumour regression in vivo. Cancer Res 2007 67(19) 9417-9424

Written By

Sarah M. Rudman, Peter G. Harper and Christopher J. Sweeney

Submitted: August 28th, 2012 Published: January 16th, 2013